Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Maximize Value

Developing strategies to accelerate the shift from volume to value

Nuclear stress tests expose patients to toxic radiation levels. We found 18 percent of physicians order them over 75 percent of the time.

Medical Director, CARDS, Providence St. Joseph Health
Principal, Oliver Wyman
Senior Consultant, Oliver Wyman
Consultant, Oliver Wyman

Ninety-five percent of employers believe it’s important Congress preserve coverage for pre-existing conditions.

Director of Employer Research for Health and Benefits, Mercer

When it comes it health benefits, paying more doesn't always get you more. But, consumers will open up their wallets for better value.

Partner, Health & Life Sciences, Oliver Wyman

A series of perspectives on the state of data in healthcare.

Live from OWHIC's Thrive Global Insights Lounge

Thrive Global interviews Optum's strategy leader about making sense of healthcare's chaos and how to get enough sleep anyway.

Insights in your inbox

Subscribe

Only 37 percent of boards over the past two years have discussed how diversity (or a lack of diversity) impacts company culture.

CEO, WomenCorporateDirectors Foundation
Director, Marsh & McLennan Insights

A closer look at how fast change may happen, who could win (and lose), and how the next decade may unfold for incumbents and new market entrants.

Partner, Health & Life Sciences, Oliver Wyman
Senior Knowledge Expert, Health & Life Sciences, Oliver Wyman

Oliver Wyman Actuarial Consulting discusses CMS changes for 2020.

Principal, Oliver Wyman Actuarial Consulting
Principal, Oliver Wyman Actuarial Consulting
Senior Consultant, Oliver Wyman
Senior Consultant, Oliver Wyman

An executive view on medicaid partnership growth.

Vice President, Medicaid Alliance, Anthem

27 partnered products were launched last year, with 70 percent joint ventured or co-branded insurance products.

Partner, Health & Life Sciences, Oliver Wyman
Engagement Manager, Oliver Wyman
Senior Consultant, Health & Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe